Why the study?
Does sustained-release procainamide improve the pharmacokinetic profile and suppress ventricular premature beats compared to ordinary tablets?
Does sustained-release procainamide improve the pharmacokinetic profile and suppress ventricular premature beats compared to ordinary tablets?
Sustained-release procainamide extends the biological half-life compared to ordinary tablets and effectively suppresses ventricular premature beats, though individual plasma level monitoring is recommended.
Answers are grounded in this paper and cite their sources.
May support less frequent dosing; leaves open whether sustained-release procainamide improves arrhythmia outcomes versus ordinary tablets.
A new sustained‐release tablet of procainamide has been found to have a mean biological half‐life of 6.7 hours as compared with 3.2 hours in ordinary tablet form. The dosage of 1.2 g t.i.d. yielded averaged plasma concentrations of 3.2–5.4 mg/1 after 24 hours. Ventricular premature beats were abolished for about 5 hours in most of the 47 patients studied. These findings suggest 1.0 g q.i.d. to be the optimum for an average patient. Because of great individual differences the determination of procainamide plasma levels in clinical use is recommended.
No takes yet. Share an insight, caveat, or question.
Arstila et al. (1974) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: